Interpace Biosciences, Inc. (IDXG)
OTCMKTS
· Delayed Price · Currency is USD
2.650
-0.250 (-8.62%)
Dec 27, 2024, 4:00 PM EST
Interpace Biosciences Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Cash & Equivalents | 2.11 | 3.5 | 4.83 | 2.67 | 2.77 | 2.32 | Upgrade
|
Cash & Short-Term Investments | 2.11 | 3.5 | 4.83 | 2.67 | 2.77 | 2.32 | Upgrade
|
Cash Growth | -58.01% | -27.55% | 80.69% | -3.61% | 19.43% | -61.75% | Upgrade
|
Accounts Receivable | 7.29 | 4.98 | 5.03 | 4.67 | 8.03 | 10.34 | Upgrade
|
Receivables | 7.29 | 4.98 | 5.03 | 4.67 | 8.03 | 10.34 | Upgrade
|
Inventory | 1.22 | 1.23 | 1.22 | 0.83 | 2.05 | 1.83 | Upgrade
|
Prepaid Expenses | 0.44 | 0.59 | 0.39 | 0.58 | 0.63 | 0.97 | Upgrade
|
Restricted Cash | - | - | - | 0.25 | 0.6 | - | Upgrade
|
Other Current Assets | 0.04 | 0.02 | 0.68 | 3.16 | 0.05 | 1.06 | Upgrade
|
Total Current Assets | 11.11 | 10.32 | 12.15 | 12.17 | 14.12 | 16.51 | Upgrade
|
Property, Plant & Equipment | 2.88 | 2.65 | 2.92 | 1.6 | 11.73 | 10.71 | Upgrade
|
Goodwill | - | - | - | - | 8.43 | 8.43 | Upgrade
|
Other Intangible Assets | - | - | 0.86 | 2.13 | 11.35 | 15.85 | Upgrade
|
Other Long-Term Assets | 0.05 | 0.05 | 0.05 | 22.53 | 0.04 | 0.04 | Upgrade
|
Total Assets | 14.04 | 13.02 | 15.98 | 38.43 | 45.68 | 51.54 | Upgrade
|
Accounts Payable | 1.7 | 1.54 | 1.05 | 1.37 | 4.51 | 4.71 | Upgrade
|
Accrued Expenses | 10.16 | 9.04 | 7.9 | 9.04 | 8.34 | 7.5 | Upgrade
|
Current Portion of Long-Term Debt | 5.69 | 5.1 | 2.5 | - | - | - | Upgrade
|
Current Portion of Leases | 0.31 | 0.38 | 0.58 | 0.76 | 1.2 | 1.51 | Upgrade
|
Current Income Taxes Payable | 0.26 | 0.26 | 0.26 | 0.22 | 0.33 | 0.4 | Upgrade
|
Current Unearned Revenue | - | - | - | - | 0.05 | 0.46 | Upgrade
|
Other Current Liabilities | 0.66 | 1.15 | 1.99 | 4.28 | 3.8 | 2.72 | Upgrade
|
Total Current Liabilities | 18.77 | 17.47 | 14.28 | 15.68 | 18.23 | 17.29 | Upgrade
|
Long-Term Debt | - | 4.24 | 11.17 | 9.44 | - | 3 | Upgrade
|
Long-Term Leases | 1.19 | 1.47 | 1.85 | 0.52 | 3.54 | 2.59 | Upgrade
|
Long-Term Unearned Revenue | - | - | - | - | 0.14 | 0.27 | Upgrade
|
Other Long-Term Liabilities | 5.23 | 4.97 | 5.22 | 8.67 | 6.32 | 6.7 | Upgrade
|
Total Liabilities | 25.19 | 28.16 | 32.52 | 34.31 | 28.23 | 29.85 | Upgrade
|
Common Stock | 0.41 | 0.41 | 0.41 | 0.4 | 0.4 | 0.39 | Upgrade
|
Additional Paid-In Capital | 188.36 | 188.15 | 187.52 | 186.11 | 184.4 | 182.51 | Upgrade
|
Retained Earnings | -244.41 | -248.22 | -249.02 | -227.06 | -212.12 | -185.67 | Upgrade
|
Treasury Stock | -2.05 | -2.01 | -1.98 | -1.87 | -1.77 | -1.72 | Upgrade
|
Total Common Equity | -57.68 | -61.67 | -63.07 | -42.42 | -29.08 | -4.48 | Upgrade
|
Shareholders' Equity | -11.15 | -15.14 | -16.54 | 4.12 | 17.45 | 21.69 | Upgrade
|
Total Liabilities & Equity | 14.04 | 13.02 | 15.98 | 38.43 | 45.68 | 51.54 | Upgrade
|
Total Debt | 7.18 | 11.19 | 16.09 | 10.72 | 4.74 | 7.1 | Upgrade
|
Net Cash (Debt) | -5.07 | -7.69 | -11.26 | -8.05 | -1.97 | -4.78 | Upgrade
|
Net Cash Per Share | -1.15 | -1.76 | -2.66 | -1.95 | -0.49 | -1.27 | Upgrade
|
Filing Date Shares Outstanding | 4.4 | 4.38 | 4.31 | 4.23 | 4.11 | 4.04 | Upgrade
|
Total Common Shares Outstanding | 4.4 | 4.35 | 4.3 | 4.2 | 4.06 | 3.92 | Upgrade
|
Working Capital | -7.66 | -7.15 | -2.13 | -3.52 | -4.11 | -0.78 | Upgrade
|
Book Value Per Share | -13.10 | -14.17 | -14.68 | -10.11 | -7.17 | -1.14 | Upgrade
|
Tangible Book Value | -57.68 | -61.67 | -63.93 | -44.55 | -48.87 | -28.76 | Upgrade
|
Tangible Book Value Per Share | -13.10 | -14.17 | -14.88 | -10.62 | -12.05 | -7.34 | Upgrade
|
Machinery | - | 2.81 | 2.55 | 2.22 | 8.21 | 6.93 | Upgrade
|
Leasehold Improvements | - | 0.27 | 0.18 | 0.18 | 0.51 | 0.51 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.